How effective is Sorafenib? Can tumors be shrunk?

Sorafenib is a prescription drug used to treat renal cell carcinoma in adults to treat Unresectable liver cancer (Hepatocellular carcinoma orHCC), treatment of a type of thyroid cancer called differentiated thyroid cancer (DTC) . In randomized, placebo-controlled studies, sorafenib has been shown to prolong overall or progression-free survival and shrink or slow tumor progression in some patients.

For patients with kidney cancer, 769 patients with kidney cancer(advanced renal cell carcinoma[RCC])received oral sorafenib 400 in the Phase 3 targeted study. mgor placebo. Median progression-free survival for patients with advanced renal cell carcinoma who received sorafenib was twice as long as those who received placebo: 24 weeks versus 12 weeks. In TARGET, patients randomized to receive sorafenib had a 28% improvement in overall survival compared with placebo (0.72) but did not reach statistical significance at the time of analysis, meaning that sorafenib could not be said to be better than placebo in prolonging survival. Tumor response was minimal. Overall, of 672 patients, 7 patients (2%) in the sorafenib group and no patients in the placebo group had a confirmed partial response.

For patients with liver cancer, in the Phase 3SHARP study, researchers looked at 602< Overall survival of patients treated with sorafenib for liver cancer with surgically unresectable tumors (unresectable hepatocellular carcinoma). Participants received oral sorafenib 400 mg twice daily or matching placebo. The median overall survival of patients treated with sorafenib was 10.7 months, compared with 7.9 months for patients taking placebo. Median time means that half the people live more than 10.7 months and the other half live less than 10.9 months. Sorafenib also significantly prolonged the time to tumor development by 42% in the sorafenib group (HR: 0.58, p=0.000007). The median number of months to tumor progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group. Progression-free survival (PFS) is the length of time during and after cancer treatment that a patient lives with the disease without getting worse.

For thyroid patients, sorafenib treatment was also studied in the DECISION trial in 417 patients with progressively differentiated thyroid cancer unresponsive to radioactive iodine therapy. The cancer either comes back or spreads in the body. Patients were randomized to receive sorafenib 400 mg twice daily or placebo.据显示，索拉非尼可将患者无癌症进展的生存期(无进展生存期)延长41%。 Half of the patients who received sorafenib survived at least 10.8 months, while those who received placebo lived for at least 5.8 months. At 10.8 months, 113 of 207 (55%) patients had died or had disease progression, compared with 136 of 210 who took placebo (65%) of patients died or had disease progression (hazard ratio0.49; p<0.001). In the final overall survival (OS) analysis, no statistically significant differences were found. In the sorafenib group, 103 of 207 (49.8%) patients died, while in the placebo group, 109 of 210 (51.9%) patients died. The median OS in the sorafenib group was 42.8 months (range was 34.6to52.6months). OS in the placebo group was 39.4 months, ranging from 32.7 to 51.4 months. The retail price of Bangladesh Yaopin International Pharmaceutical 0.2g*120 tablets is about 700 yuan. The retail price of pharmaceuticals in Laos and ASEAN is about 0.2g*56 tablets500yuan. IndiaNATCOPharmaceutical retail price0.2g*120tablets1000yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.